Natalizumab: a new hope for Crohn's disease?
Napier
John
J
Uniformed Services University of the Health Sciences, Gastroenterology Service, Division of Digestive Diseases, Walter Reed Army Medical Center, Washington, DC, USA.
Wong
Roy K H
RK
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002097:C-Reactive Protein / Q000032:analysis; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007262:Infusions, Intravenous; D000069442:Natalizumab; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D002097:C-Reactive Protein